Johnson & Johnson’s RYBREVANT plus chemotherapy shows record overall survival in EGFR exon20‑insertion lung cancer, signaling a potential new standard of care
Executive summary: Johnson & Johnson announced that its EGFR‑MET bispecific antibody RYBREVANT (amivantamab‑vmjw) combined with chemotherapy delivered the longest reported median overall survival in patients with EGFR exon20 insertion‑positive lung cancer. This addresses a poor‑prognosis patient subset whose historical five‑year survival is only about 8%; a new effective regimen could shift treatment guidelines and generate meaningful oncology revenue for J&J.
Who is involved: Johnson & Johnson, clinicians and patients with EGFR exon20 insertion NSCLC, and the study investigators who presented the data in Seoul.
Likely next: The company is expected to submit the data to regulators for label expansion, while competitors may accelerate their own EGFR/MET programs.
The press release reports that the combination of amivantamab‑vmjw and chemotherapy achieved the longest median overall survival ever seen in patients with EGFR exon20 insertion‑positive non‑small cell lung cancer, a group with a historical five‑year survival of about 8%. The data were presented at a medical meeting in Seoul and suggest a differentiated mechanism that simultaneously targets EGFR and MET pathways. While the results are promising, they are based on a single study and await regulatory review before any change in clinical practice.
What's next — scenarios
Base: Regulatory approval and standard‑of‑care adoption (50%)
RYBREVANT+chemo becomes a new option for EGFR exon20 insertion NSCLC, boosting J&J’s oncology sales.
- FDA grants regular approval for the supplemental BLA within the next 6 months
- Positive readout of the confirmatory phase III trial
Upside: Earlier‑line or monotherapy approval (30%)
Expanded use in first‑line settings or as monotherapy increases patient uptake and market share.
- Phase II trial shows efficacy in first‑line EGFR exon20 insertion NSCLC
- Publication of real‑world evidence supporting earlier‑line use
Downside: Safety or competitive setbacks (20%)
Adoption is limited by adverse‑event concerns or the launch of a rival EGFR/MET inhibitor with superior efficacy.
- Post‑marketing surveillance identifies significant safety signals
- Competitor receives approval for a differentiated EGFR/MET therapy with better survival data
What to watch
- FDA decision on J&J’s supplemental BLA for RYBREVANT in EGFR exon20 insertion NSCLC
- Presentation of overall survival data at an upcoming oncology conference (e.g., IASLC World Conference on Lung Cancer 2026)
- Johnson & Johnson’s quarterly earnings report highlighting oncology segment performance
- Readout of a competing EGFR/MET inhibitor’s phase III trial
Timeline
- — Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer (PR Newswire)
- — Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 (PR Newswire)
- — Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer (PR Newswire)
Analysis — what this means
Sectors affected
- Non‑small cell lung cancer EGFR exon20 insertion targeted therapy
- Pharmaceutical oncology
Historical parallels
- Johnson & Johnson’s RYBREVANT FASPRO received U.S. FDA Priority Review for EGFR‑ and MET‑targeted subcutaneous treatment in advanced head and neck cancer (July 2026)
Key entities
Sources
- Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer — PR Newswire
- Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 — PR Newswire
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer — PR Newswire